“Limited Clinical Activity of Pembrolizumab Combined with Itacitinib or Parsaclisib in Advanced Solid Tumors: A Phase I Study”

https://pubmed.ncbi.nlm.nih.gov/38115208

This phase I study found that combining pembrolizumab (PD-1 inhibitor) with either itacitinib (JAK1 inhibitor) or parsaclisib (PI3Kδ inhibitor) in patients with advanced solid tumors showed limited clinical activity and little effect on T-cell infiltration in the tumor, and thus does not support continued development of these combinations.